A study explored the prognostic value of lower urinary tract symptoms (LUTS) in patients with newly diagnosed regional lymph node-positive prostate cancer.
Researchers assessed the prognostic value of LUTS for predicting progression-free (PFS) and overall (OS) survival, as well as the differential prognostic impact of radiotherapy by LUTS.
The Univariate Cox-model analysis demonstrated a statistically significantly increased hazard risk for PFS and OS for men with International Prostate Symptom Score (IPSS) ≥19 and Overactive Bladder Symptom Score (OABSS) ≥8 at diagnosis. Patients with lower IPSS had a greater five-year PFS (70.0% vs. 51.9%, P=0.027) and OS (89.3% vs. 73.6%, P=0.016) compared with patients with higher IPSS. Similarly, a lower OABSS was associated with greater PFS (67.4% vs. 23.4%, P<0.001) and OS (85.3% vs. 57.1%, P=0.012) at five years compared with higher OABSS.
“IPSS and OABSS were prognostic for PFS and OS in patients with regional lymph node-metastatic prostate cancer,” the researchers concluded.